Related references
Note: Only part of the references are listed.JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles
Jaime A. Castro-Mondragon et al.
NUCLEIC ACIDS RESEARCH (2022)
Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance
Mark A. Tye et al.
NATURE COMMUNICATIONS (2022)
Metabolic markers for diagnosis and risk-prediction of multiple myeloma
Fei Fei et al.
LIFE SCIENCES (2021)
Bright and stable luminescent probes for target engagement profiling in live cells
N. Connor Payne et al.
NATURE CHEMICAL BIOLOGY (2021)
Targeting the Integrated Stress Response in Cancer Therapy
Xiaobing Tian et al.
FRONTIERS IN PHARMACOLOGY (2021)
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Samuel A. Kerk et al.
NATURE REVIEWS CANCER (2021)
Proteasome inhibition in multiple myeloma: lessons for other cancers
Paula Saavedra-Garcia et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2020)
Aminoacyl-tRNA synthetase inhibition activates a pathway that branches from the canonical amino acid response in mammalian cells
Yeonjin Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Drug Targeting of Genomic Instability in Multiple Myeloma
Meral Beksac et al.
FRONTIERS IN GENETICS (2020)
Proline Metabolism in Tumor Growth and Metastatic Progression
Cristina D'Aniello et al.
FRONTIERS IN ONCOLOGY (2020)
Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis
Zhe Sha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Aminoacyl-tRNA synthetases as therapeutic targets
Nam Hoon Kwon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Glutamyl-prolyl-tRNA synthetase induces fibrotic extracellular matrix via both transcriptional and translational mechanisms
Dae-Geun Song et al.
FASEB JOURNAL (2019)
The Encyclopedia of DNA elements (ENCODE): data portal update
Carrie A. Davis et al.
NUCLEIC ACIDS RESEARCH (2018)
The GAIT translational control system
Abul Arif et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2018)
Bi-allelic Mutations in EPRS, Encoding the Glutamyl-Prolyl-Aminoacyl-tRNA Synthetase, Cause a Hypomyelinating Leukodystrophy
Marisa I. Mendes et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2018)
Translational Control through Differential Ribosome Pausing during Amino Acid Limitation in Mammalian Cells
Alicia M. Darnell et al.
MOLECULAR CELL (2018)
Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma
Rhamy Zeid et al.
NATURE GENETICS (2018)
Analysis of the Metabolic Characteristics of Serum Samples in Patients With Multiple Myeloma
Haiwei Du et al.
FRONTIERS IN PHARMACOLOGY (2018)
Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma
J. R. Nair et al.
LEUKEMIA (2017)
The therapeutic potential of cell cycle targeting in multiple myeloma
Anke Maes et al.
ONCOTARGET (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway
Rachel L. Wolfson et al.
CELL METABOLISM (2017)
Defining a Cancer Dependency Map
Aviad Tsherniak et al.
CELL (2017)
Discovery of a novel prolyl-tRNA synthetase inhibitor and elucidation of its binding mode to the ATP site in complex with L-proline
Ryutaro Adachi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Loss-of-Function Alanyl-tRNA Synthetase Mutations Cause an Autosomal-Recessive Early-Onset Epileptic Encephalopathy with Persistent Myelination Defect
Cas Simons et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2015)
Halofuginone - The Multifaceted Molecule
Mark Pines et al.
MOLECULES (2015)
The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs
Jonathan D. Herman et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine
Mohamed R. Akl et al.
ONCOTARGET (2015)
The small molecule ISRIB reverses the effects of elF2α phosphorylation on translation and stress granule assembly
Carmela Sidrauski et al.
ELIFE (2015)
Keeping the eIF2 alpha kinase Gcn2 in check
Beatriz A. Castilho et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Triazolo[4,5-d]pyrimidine Derivatives as Inhibitors of GCN2
Jean-Francois Brazeau et al.
ACS Medicinal Chemistry Letters (2014)
A genomic and evolutionary approach reveals non-genetic drug resistance in malaria
Jonathan D. Herman et al.
GENOME BIOLOGY (2014)
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents
Merav Leiba et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
Dharminder Chauhan et al.
CANCER CELL (2012)
Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome Inhibition
Amila Suraweera et al.
MOLECULAR CELL (2012)
An integrated encyclopedia of DNA elements in the human genome
Ian Dunham et al.
NATURE (2012)
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase
Tracy L. Keller et al.
NATURE CHEMICAL BIOLOGY (2012)
Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC
Wei Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17
C. Zhao et al.
ONCOGENE (2008)
Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment
Constantine S. Mitsiades et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
Silke Meister et al.
CANCER RESEARCH (2007)
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours
M. J. A. de Jonge et al.
EUROPEAN JOURNAL OF CANCER (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Translational regulation of GCN4 and the general amino acid control of yeast
AG Hinnebusch
ANNUAL REVIEW OF MICROBIOLOGY (2005)
Advances in biology of multiple myeloma: clinical applications
T Hideshima et al.
BLOOD (2004)
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
AH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
E2A-HLF usurps control of evolutionarily conserved survival pathways
MG Seidel et al.
ONCOGENE (2001)
Share Paper
